Share 0 Post 0 Share 0 Post 0 Portugal is using the global stage at Expo 2025 in Osaka to highlight its growing life sciences sector, including advances in biotechnology, pharmaceuticals and digital health.The country’s exhibition, part of its wider presence at the international fair, is designed to attract foreign investment and partnerships. Organisers say […]
Congratulations to the Biorce team on securing €5 million to scale AI in clinical trials!The Barcelona-based startup is transforming how trials are designed and executed with Jarvis — their AI-native platform trained on over 500,000 studies. This round, led by Norrsken VC, will help them expand into new markets and empower pharma teams to plan
Pharmaceutical giant AstraZeneca has announced it will establish a major strategic hub in Lisbon, reinforcing Portugal’s growing role in the global life sciences sector. The British-Swedish multinational plans to create a multidisciplinary centre in the capital that will focus on research and development, operational support, and digital innovation. The new site will be located in
Portugal’s biotechnology and pharmaceutical sectors have become the backbone of the country’s health-related exports, accounting for more than 80 percent of the total value of goods exported within the health industry, according to figures published by AICEP, Portugal’s national agency for trade and investment. This export dominance signals a maturing life sciences ecosystem and a
The Portuguese Bioindustry Association, P-BIO, has unveiled its strategic roadmap for the country’s life sciences sector, laying out a bold and long-term vision under the title BIO-HEALTH 2030. The document outlines how Portugal can position itself as a major European hub for innovation in biotechnology, health technologies, and advanced therapies over the next five years.The
The Spanish bioindustry has reported record levels of investment, underlining its growing importance as a pillar of the national economy and a hub for scientific innovation in Europe. According to data published by the Spanish Bioindustry Association (AseBio), companies operating in the biotechnology and life sciences sectors attracted more than €200 million in private capital
Spanish pharmaceutical and diagnostics group Grifols appears to be regaining stability after a turbulent financial year marked by investor uncertainty, public scrutiny, and significant restructuring. The company, based in Barcelona and best known for its leadership in plasma-derived medicines, experienced a series of challenges in 2024 that included a short-seller attack, questions over its accounting
BIAL, Portugal’s century-old biopharmaceutical champion, has become a founding member of the Orphan Therapeutics Accelerator (OTXL), a nonprofit biotech initiative launched in June 2024 to revive and advance treatments for ultra rare diseases.In a statement released in April 2025, BIAL confirmed its commitment to help identify, develop, and commercialize two to three discontinued therapeutic programs
In a pivotal EU competitiveness council held in Budapest last week, Spain’s Industry Minister Jordi Hereu called on the European Union to take bolder action in supporting the biotech sector. His message was clear: Europe’s biotechnology future hinges on greater support for small and medium-sized enterprises (SMEs), regulatory modernization, and expanded bioproduction capabilities.The EU’s Informal
In a clear signal of investor confidence in Spain’s growing biotech landscape, Italian private equity firm Ambienta SGR has acquired Agronova Biotech, a Spain-based leader in agricultural biotechnology. The deal represents Ambienta’s first major investment in the Spanish biotech sector, positioning the firm at the forefront of sustainable agri-innovation in southern Europe.Based in Andalusia, Agronova
